Baird Initiates Coverage on Regeneron (REGN) with a Neutral
More News related to REGN
- BioMed Realty (BMR) To Lease 131K Sq. Ft. From Regeneron Pharma (REGN)
- BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
- Regeneron Announces Presentation at the 21st Annual Piper Jaffray Healthcare Conference
- Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
More News related to New Coverage
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
Baird initiates coverage on Regeneron (Nasdaq: REGN) with a Neutral rating.
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Related Categories
New CoverageStocks Mentioned
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
